PMC:7408073 / 95934-96642
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T510 | 417-421 | Body_part | denotes | axis | http://purl.org/sig/ont/fma/fma12520 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
3347 | 55-59 | Gene | denotes | ACE2 | Gene:59272 |
3348 | 173-177 | Gene | denotes | ACE2 | Gene:59272 |
3349 | 326-330 | Gene | denotes | ACE2 | Gene:59272 |
3350 | 397-401 | Gene | denotes | ACE2 | Gene:59272 |
3351 | 431-435 | Gene | denotes | ACE2 | Gene:59272 |
3352 | 456-459 | Gene | denotes | ACE | Gene:59272 |
3353 | 460-464 | Gene | denotes | ACE2 | Gene:59272 |
3354 | 613-617 | Gene | denotes | ACE2 | Gene:59272 |
3355 | 644-648 | Gene | denotes | MasR | Gene:116511 |
3356 | 668-673 | Gene | denotes | renin | Gene:5972 |
3357 | 412-416 | Gene | denotes | MasR | Gene:116511 |
3358 | 101-109 | Species | denotes | patients | Tax:9606 |
3359 | 283-293 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3360 | 402-410 | Gene | denotes | Ang (1–7 | Gene:27329 |
3361 | 692-697 | Chemical | denotes | metal | MESH:D008670 |
3362 | 92-100 | Disease | denotes | COVID-19 | MESH:C000657245 |
3363 | 539-546 | Disease | denotes | hypoxia | MESH:D000860 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T543 | 92-100 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T544 | 283-291 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T545 | 283-287 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1169 | 143-144 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T1170 | 229-235 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | active |
T1171 | 245-247 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T22916 | 618-636 | Chemical | denotes | pathway inhibitors | http://purl.obolibrary.org/obo/CHEBI_76932 |
T430 | 626-636 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T28021 | 649-660 | Chemical | denotes | antagonists | http://purl.obolibrary.org/obo/CHEBI_48706 |
T432 | 674-684 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T48464 | 698-707 | Chemical | denotes | chelators | http://purl.obolibrary.org/obo/CHEBI_38161 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T465 | 0-110 | Sentence | denotes | Based on the above described hypothesis, inhibition of ACE2 pathway might be beneficial for COVID-19 patients. |
T466 | 111-371 | Sentence | denotes | Indeed, the clinical picture as a whole is consistent with an ACE2 gain of function (possibly due to both circulating active forms of S1-sACE2 complexes and local forms of SARS-CoV-2-sACE2 complexes) rather than an ACE2 loss of function, as initially supposed. |
T467 | 372-566 | Sentence | denotes | Therefore, inhibition of ACE2/Ang (1–7)/MasR axis or other ACE2 pathways to restore ACE/ACE2 balance might be needed, at least in the first phases of the disease when hypoxia is not yet induced. |
T468 | 567-708 | Sentence | denotes | Different strategies could be pursued through ACE2 pathway inhibitors and/or MasR antagonists and/or renin inhibitors and/or metal chelators. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T159 | 539-546 | Phenotype | denotes | hypoxia | http://purl.obolibrary.org/obo/HP_0012418 |